Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges.

[1]  Ruijiang Li,et al.  A Quantitative CT Imaging Signature Predicts Survival and Complements Established Prognosticators in Stage I Non-Small Cell Lung Cancer. , 2018, International journal of radiation oncology, biology, physics.

[2]  S. Hanash,et al.  Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins , 2018, JAMA oncology.

[3]  L. Wain,et al.  Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk , 2018, Nature Communications.

[4]  B. Hennessy,et al.  Brief Report on the Detection of the EGFR T790M Mutation in Exhaled Breath Condensate from Lung Cancer Patients , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  I. Wistuba,et al.  A novel protein‐based prognostic signature improves risk stratification to guide clinical management in early‐stage lung adenocarcinoma patients , 2018, The Journal of pathology.

[6]  S. Plevritis,et al.  Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study. , 2018, Journal of Clinical Oncology.

[7]  D. Wood.  POINT: Should Lung Cancer Screening Be Expanded to Persons Who Don't Currently Meet Accepted Criteria Set Forth by the CHEST Guidelines on Lung Cancer Screening? Yes. , 2018, Chest.

[8]  J. Jett,et al.  Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules , 2018, PloS one.

[9]  J. Benítez,et al.  Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco‐induced lung cancer , 2018, Cancer medicine.

[10]  K. Brothers,et al.  Tensions in ethics and policy created by National Precision Medicine Programs , 2018, Human Genomics.

[11]  P. Mazzone,et al.  Screening for Lung Cancer: CHEST Guideline and Expert Panel Report , 2018, Chest.

[12]  Maximilian Diehn,et al.  Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. , 2018, Archives of pathology & laboratory medicine.

[13]  Brooke L. Billman,et al.  Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Paul Kearney,et al.  Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules , 2018, Chest.

[15]  Ludmila V. Danilova,et al.  Detection and localization of surgically resectable cancers with a multi-analyte blood test , 2018, Science.

[16]  M. Lenburg,et al.  The Airway Transcriptome as a Biomarker for Early Lung Cancer Detection , 2018, Clinical Cancer Research.

[17]  P. Mazzone,et al.  Evaluation of a Serum Lung Cancer Biomarker Panel , 2018, Biomarker insights.

[18]  Daniel R. Schrider,et al.  Supervised Machine Learning for Population Genetics: A New Paradigm , 2018, Trends in genetics : TIG.

[19]  H. Blons,et al.  Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer , 2018, Oncoimmunology.

[20]  P. Massion,et al.  Complement C4d-specific antibodies for the diagnosis of lung cancer , 2017, Oncotarget.

[21]  Witold Rzyman,et al.  European position statement on lung cancer screening. , 2017, The Lancet. Oncology.

[22]  Kefeng Li,et al.  Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review , 2017, Oncotarget.

[23]  Bram van Ginneken,et al.  Malignancy risk estimation of pulmonary nodules in screening CTs: Comparison between a computer model and human observers , 2017, PloS one.

[24]  S. Lam,et al.  Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. , 2017, The Lancet. Oncology.

[25]  Lin Wang,et al.  DNA Methylation Analysis of the SHOX2 and RASSF1A Panel in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis , 2017, Journal of Cancer.

[26]  Charles A Powell,et al.  Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement , 2017, American journal of respiratory and critical care medicine.

[27]  Wei-min Li,et al.  Development and clinical application of radiomics in lung cancer , 2017, Radiation oncology.

[28]  Yun Zhou,et al.  A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules , 2017, International journal of cancer.

[29]  Guopeng Zhang,et al.  Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers , 2017, PloS one.

[30]  N. Tanner,et al.  Assessing the Generalizability of the National Lung Screening Trial: Comparison of Patients with Stage 1 Disease , 2017, American journal of respiratory and critical care medicine.

[31]  Edward S. Kim,et al.  Prognostic and predictive biomarkers post curative intent therapy. , 2017, Annals of translational medicine.

[32]  H. Pass,et al.  A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA , 2017, Clinical Cancer Research.

[33]  T. Cai,et al.  Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies , 2017, Scientific Reports.

[34]  Sam Angiuoli,et al.  Direct detection of early-stage cancers using circulating tumor DNA , 2017, Science Translational Medicine.

[35]  P. Lambin,et al.  Defining the biological basis of radiomic phenotypes in lung cancer , 2017, eLife.

[36]  John Quackenbush,et al.  Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer. , 2017, Cancer research.

[37]  P. Jänne,et al.  Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  Aegis Study Team.  Shared Gene Expression Alterations in Nasal and Bronchial Epithelium for Lung Cancer Detection. , 2017 .

[39]  Zhijun Liu,et al.  The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer , 2017, BioMed research international.

[40]  William S. Bush,et al.  Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes , 2017, Nature Genetics.

[41]  Ashwini Naik,et al.  Phylogenetic ctDNA analysis depicts early stage lung cancer evolution , 2017, Nature.

[42]  Harry J de Koning,et al.  Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study , 2017, PLoS medicine.

[43]  U. Pastorino,et al.  Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[44]  F. Mair,et al.  Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial , 2017, BMC Cancer.

[45]  J. Robertson,et al.  Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule‐Based Risk Models for Detection of Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[46]  Mark Lee,et al.  Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection , 2017, Cell.

[47]  R. Tetzner,et al.  Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[48]  H. Haick,et al.  Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules , 2016, ACS nano.

[49]  J. Chun,et al.  Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. , 2016, Lung cancer.

[50]  Gilles Blanchard,et al.  Combining Multiple Hypothesis Testing with Machine Learning Increases the Statistical Power of Genome-wide Association Studies , 2016, Scientific Reports.

[51]  F. Jiang,et al.  A Prediction Model Based on Biomarkers and Clinical Characteristics for Detection of Lung Cancer in Pulmonary Nodules12 , 2016, Translational oncology.

[52]  J. Herman,et al.  Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum , 2016, Clinical Cancer Research.

[53]  Dennis J. Hazelett,et al.  The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[54]  Hans J Lee,et al.  The Percepta Registry: A Prospective Registry to Evaluate Percepta Bronchial Genomic Classifier Patient Data , 2016 .

[55]  P. Massion,et al.  The Pursuit of Noninvasive Diagnosis of Lung Cancer , 2016, Seminars in Respiratory and Critical Care Medicine.

[56]  Yang Liu,et al.  Circulating tumor DNA detection in lung cancer patients before and after surgery , 2016, Scientific Reports.

[57]  Y. Liu,et al.  Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas. , 2016, Clinical lung cancer.

[58]  Jieun Park,et al.  Characterization of microbiome in patients with lung cancer comparing with benign mass-like lesions , 2016 .

[59]  G. Silvestri,et al.  Clinical Utility of a Bronchial Genomic Classifier in Patients With Suspected Lung Cancer. , 2016, Chest.

[60]  P. V. van Ooijen,et al.  Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval , 2016, Thorax.

[61]  M. Broggini,et al.  Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS , 2016, Oncotarget.

[62]  Hossam Haick,et al.  Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[63]  John K Field,et al.  The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. , 2016, Health technology assessment.

[64]  V. Backman,et al.  Procedures for risk-stratification of lung cancer using buccal nanocytology. , 2016, Biomedical optics express.

[65]  Oliver Fiehn,et al.  Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer. , 2016, Cancer biomarkers : section A of Disease markers.

[66]  M. Beckmann,et al.  The metabolomic detection of lung cancer biomarkers in sputum. , 2016, Lung cancer.

[67]  William J Blot,et al.  Urinary Metabolite Risk Biomarkers of Lung Cancer: A Prospective Cohort Study , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[68]  F. Priego-Capote,et al.  Identification of metabolomics panels for potential lung cancer screening by analysis of exhaled breath condensate , 2016, Journal of breath research.

[69]  Bram van Ginneken,et al.  Pulmonary Nodule Detection in CT Images: False Positive Reduction Using Multi-View Convolutional Networks , 2016, IEEE Transactions on Medical Imaging.

[70]  G. Kennedy,et al.  Analytical performance of a bronchial genomic classifier , 2016, BMC Cancer.

[71]  J. Dopazo,et al.  Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer , 2016, Oncotarget.

[72]  A. Agustí,et al.  Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer. , 2016, American journal of respiratory and critical care medicine.

[73]  C. la Vecchia,et al.  Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening , 2015, Oncotarget.

[74]  Christy A. Lancaster,et al.  The Cell‐CT 3‐dimensional cell imaging technology platform enables the detection of lung cancer using the noninvasive LuCED sputum test , 2015, Cancer cytopathology.

[75]  M. Lemieux,et al.  Early Detection of Lung Cancer with Meso Tetra (4-Carboxyphenyl) Porphyrin-Labeled Sputum , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[76]  N. Peled,et al.  Screening for Lung Cancer: What Comes Next? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Oliver Fiehn,et al.  Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  G. Silvestri,et al.  A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. , 2015, The New England journal of medicine.

[79]  M. Wielscher,et al.  Diagnostic Performance of Plasma DNA Methylation Profiles in Lung Cancer, Pulmonary Fibrosis and COPD , 2015, EBioMedicine.

[80]  Wei Shen,et al.  Multi-scale Convolutional Neural Networks for Lung Nodule Classification , 2015, IPMI.

[81]  Massimo Bellomi,et al.  miR-Test: a blood test for lung cancer early detection. , 2015, Journal of the National Cancer Institute.

[82]  U. Pastorino,et al.  Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging , 2015, Expert review of molecular diagnostics.

[83]  J. Jett,et al.  Progress in the development of volatile exhaled breath signatures of lung cancer. , 2015, Annals of the American Thoracic Society.

[84]  Avrum Spira,et al.  Derivation of a bronchial genomic classifier for lung cancer in a prospective study of patients undergoing diagnostic bronchoscopy , 2015, BMC Medical Genomics.

[85]  J. Weissfeld,et al.  Improving selection criteria for lung cancer screening. The potential role of emphysema. , 2015, American journal of respiratory and critical care medicine.

[86]  V. Doseeva,et al.  Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer , 2015, Journal of Translational Medicine.

[87]  G. Apolone,et al.  Smoking Cessation Intervention Within the Framework of a Lung Cancer Screening Program: Preliminary Results and Clinical Perspectives from the “Cosmos-II” Trial , 2015, Lung.

[88]  B. Celli,et al.  Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. , 2015, American journal of respiratory and critical care medicine.

[89]  Jian Su,et al.  Sputum microRNA Biomarkers for Identifying Lung Cancer in Indeterminate Solitary Pulmonary Nodules , 2015, Clinical Cancer Research.

[90]  Dong Liang,et al.  The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling , 2014, Clinical Cancer Research.

[91]  W. Rom.  Biomarkers for lung cancer. , 2014, Respiratory investigation.

[92]  Francisco J. Planes,et al.  In-Silico Prediction of Key Metabolic Differences between Two Non-Small Cell Lung Cancer Subtypes , 2014, PloS one.

[93]  Emmanuel Hatzakis,et al.  Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. , 2014, Cancer research.

[94]  Christy A. Lancaster,et al.  Early detection of lung cancer based on three-dimensional, morphometric analysis of cells from sputum. , 2014 .

[95]  S. de Lusignan,et al.  Genetic test to stop smoking (GeTSS) trial protocol: randomised controlled trial of a genetic test (Respiragene) and Auckland formula to assess lung cancer risk , 2014, BMC Pulmonary Medicine.

[96]  C. la Vecchia,et al.  Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  V. Moyer.  Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2014, Annals of Internal Medicine.

[98]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[99]  Heidi Roberts,et al.  Screening High-Risk Populations for Lung Cancer: Guideline Recommendations , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[100]  S. Lam,et al.  Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer. , 2013, Journal of thoracic disease.

[101]  P. Massion,et al.  Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. , 2013, Journal of the National Cancer Institute.

[102]  Radu Ionescu,et al.  Volatile fingerprints of cancer specific genetic mutations. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[103]  Timothy R Church,et al.  Selection criteria for lung-cancer screening. , 2013, The New England journal of medicine.

[104]  J. Robertson,et al.  Application of a High Throughput Method of Biomarker Discovery to Improvement of the EarlyCDT®-Lung Test , 2012, PloS one.

[105]  H. Haick,et al.  Non-invasive Breath Analysis of Pulmonary Nodules , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[106]  Hossam Haick,et al.  Volatile organic compounds of lung cancer and possible biochemical pathways. , 2012, Chemical reviews.

[107]  C. Berg,et al.  Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? , 2012, Journal of medical screening.

[108]  P. Boyle,et al.  EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays , 2012, Tumor Biology.

[109]  Patrick Granton,et al.  Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.

[110]  J. Jett,et al.  Added Value of a Serum Proteomic Signature in the Diagnostic Evaluation of Lung Nodules , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[111]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[112]  Massimo Bellomi,et al.  Lung Cancer Risk Prediction to Select Smokers for Screening CT—a Model Based on the Italian COSMOS Trial , 2011, Cancer Prevention Research.

[113]  Patrick Maisonneuve,et al.  A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer , 2011, EMBO molecular medicine.

[114]  P. Prorok,et al.  Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. , 2011, Journal of the National Cancer Institute.

[115]  S. Lam,et al.  EarlyCDT-Lung: An Immunobiomarker Test as an Aid to Early Detection of Lung Cancer , 2011, Cancer Prevention Research.

[116]  Ugo Pastorino,et al.  MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer , 2011, Proceedings of the National Academy of Sciences.

[117]  P. Boyle,et al.  Clinical validation of an autoantibody test for lung cancer , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[118]  H. Haick,et al.  Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors , 2010, British Journal of Cancer.

[119]  Christopher R Kinsinger,et al.  Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. , 2010, Clinical chemistry.

[120]  Malik Yousef,et al.  Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. , 2009, Cancer research.

[121]  M. Ehrlich.  DNA hypomethylation in cancer cells. , 2009, Epigenomics.

[122]  Thomas M. Blomquist,et al.  Pattern of antioxidant and DNA repair gene expression in normal airway epithelium associated with lung cancer diagnosis. , 2009, Cancer research.

[123]  Zhenqiu Liu,et al.  Combined genetic analysis of sputum and computed tomography for noninvasive diagnosis of non-small-cell lung cancer. , 2009, Lung cancer.

[124]  S. Duffy,et al.  The LLP risk model: an individual risk prediction model for lung cancer , 2007, British Journal of Cancer.

[125]  P. Sebastiani,et al.  Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer , 2007, Nature Medicine.

[126]  J. Jett,et al.  A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. , 2006, Chest.

[127]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[128]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[129]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[130]  R. Dziadziuszko,et al.  Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study. , 2017, Acta biochimica Polonica.

[131]  Joseph F. Perez-Rogers,et al.  Shared Gene Expression Alterations in Nasal and Bronchial Epithelium for Lung Cancer Detection , 2017, Journal of the National Cancer Institute.

[132]  J. Jett,et al.  udit of the autoantibody test , EarlyCDT ®-Lung , in 1600 patients : n evaluation of its performance in routine clinical practice , 2014 .

[133]  William E Grizzle,et al.  Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. , 2009, Journal of proteome research.

[134]  O. Miettinen,et al.  CT screening for lung cancer: significance of diagnoses in its baseline cycle. , 2006, Clinical imaging.

[135]  G. Byrnes,et al.  Screening for lung cancer. , 2004, The Cochrane database of systematic reviews.

[136]  J. Herman,et al.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.